These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27234033)

  • 1. Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer.
    Igawa S; Sasaki J; Otani S; Shirasawa M; Niwa H; Kusuhara S; Harada S; Kubota M; Katagiri M; Masuda N
    Oncology; 2016; 91(1):41-7. PubMed ID: 27234033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
    Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
    Igawa S; Sasaki J; Otani S; Ishihara M; Takakura A; Katagiri M; Masuda N
    Oncology; 2015; 89(5):275-80. PubMed ID: 26335629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
    Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
    Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
    Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
    Jo J; Kim SH; Kim YJ; Lee J; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Chung JH; Jeon YK; Lee JS
    Yonsei Med J; 2018 Mar; 59(2):202-210. PubMed ID: 29436187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
    Hata A; Katakami N; Hattori Y; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):689-695. PubMed ID: 28280972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).
    Hata A; Katakami N; Fujita S; Nanjo S; Takeshita J; Tanaka K; Kaneda T; Nishiyama A; Nishimura T; Nakagawa A; Otsuka K; Morita S; Urata Y; Negoro S
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1267-72. PubMed ID: 25925001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.